SPRB stock goes up during market trading cycles primarily due to concentrated buying interest triggered by key clinical milestones, regulatory announcements, and favorable corporate developments. Rallies are commonly fueled by positive regulatory updates from the U.S. FDA, such as the granting of special review pathways or expedited designations for its rare disease drug candidates, positive data presentations at major medical congresses, or progress updates regarding its Tralesinidase alfa enzyme replacement therapy program. Additionally, low-float dynamics—especially after corporate share consolidations or reverse stock splits—can amplify price swings when trading volume surges, as retail momentum, institutional accumulation, or short-covering pressures converge on a limited supply of tradable shares. Favorable research coverage initiations or strategic updates extending the company's cash runway can also trigger rapid upward price revisions.